Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4252 - Prognostic impact of inflammation-based scores in esophageal cancer patients achieving pathologic complete response after neoadjuvant chemoradiotherapy followed by surgery

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Immunology

Tumour Site

Oesophageal Cancer

Presenters

Jihoon Kang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

J. Kang1, H. Im2, Y. Kim3, H.R. Kim3, J.H. Kim4, H. Jung5, G. Lee5, H.J. Song5, D.H. Kim5, K.D. Choi5, J.H. Lee5, J.Y. Ahn5, J. Ryu6, K. Cho7, S. Kim8, S.R. Park2

Author affiliations

  • 1 Division Of Hematology/oncology, Department Of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181 - Seoul/KR
  • 2 Department Of Oncology, Asan Medical Center, 05505 - seoul/KR
  • 3 Department Of Thoracic Surgery, Asan Medical Center, 05505 - seoul/KR
  • 4 Department Of Radiation oncology, Asan Medical Center, 05505 - seoul/KR
  • 5 Department Of Gastroenterology, Asan Medical Center, 05505 - seoul/KR
  • 6 Department Of Nuclear Medicine, Asan Medical Center, 05505 - seoul/KR
  • 7 Department Of Pathology, Asan Medical Center, 05505 - seoul/KR
  • 8 ., Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4252

Background

Patients achieving pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery for locally advanced esophageal squamous cell carcinoma (ESCC) have a favorable prognosis. However, about 20–30% of the patients still suffer recurrences, and there are few studies evaluating prognostic factors in these patients. This retrospective analysis was performed to identify the prognostic factors in ESCC patients with pCR after NCRT followed by surgery.

Methods

Among 234 patients with ESCC who were treated with NCRT followed by surgery between 2007 and 2014 at Asan Medical Center in South Korea, 108 patients who achieved pCR (n = 108, 46.2%) were included in this analysis. Clinical, pathologic, treatment, and laboratory factors including inflammation-based scores such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and modified Glasgow prognostic score (mGPS) were included in univariate and multivariate analysis using the Cox-proportional hazards model.

Results

With the median follow-up duration of 84.5 months (range, 1.3–139.9), 10 patients (9.2%) had recurrent disease. The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 71.9% and 71.5%, respectively. In multivariate analysis, advanced clinical T stage (T3/4 vs.1/2: HR = 2.7; 95% CI, 1.37–5.16; p = 0.004), higher post-NCRT PLR (≥167.4: HR = 2.0; 95% CI, 1.01–3.78; p = 0.048), and age ≥65 years (HR = 2.4; 95% CI, 1.25–4.71; p = 0.009) were independent poor prognostic factors for OS. Advanced clinical T stage (T3/4 vs.1/2: HR = 2.7; 95% CI, 1.31–5.65; p = 0.007), higher post-NCRT PLR (≥167.4: HR = 2.1; 95% CI, 1.00–4.20; p = 0.049), and age ≥65 years (HR = 2.1; 95% CI, 1.02–4.21; p = 0.044) were also significant adverse prognostic factors for RFS. The 5-year OS rates according to number of risk factors (0/1 vs. 2 vs. 3) were 84.9%, 59.1%, and 43.6%, respectively.

Conclusions

Post-NCRT PLR together with age and pretreatment clinical T stage might be useful in identifying patients with a poor prognosis even after achieving pCR with NCRT plus surgery.

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.